**Ginsenoside Rb1 protects PC12 cells against β-amyloid-induced cell injury**

XIA XIE1,2, HAI-TAO WANG3, CHUN-LI LI4, XU-HONG GAO1, JIN-LAN DING1, HAI-HUA ZHAO3 and YONG-LI LU1

1Department of Anatomy, Basic Medical Sciences College, China Medical University, Liaoning 110001; 2Department of Anatomy, Medical College, Dalian University, Liaoning 116622; 3Department of Histology and Embryology, North China Coal Medical University, Hebei 063000; 4Institute for Biomedical Sciences of Pain and Institute for Functional Brain Disorders, Tangdu Hospital, Fourth Military Medical University, Shanxi 710038, P.R. China

Received February 5, 2010; Accepted April 19, 2010

**DOI:** 10.3892/mmr_00000308

**Abstract.** Excessive accumulation of β-amyloid (Aβ) has been proposed as a pivotal event in the pathogenesis of Alzheimer's disease. Possible mechanisms underlying Aβ-induced neuronal cytotoxicity include oxidative stress and apoptosis. Reactive oxygen species (ROS) have been proposed to be involved in the apoptotic mechanism of Aβ-induced cytotoxicity. Ginsenoside Rb1 (Grb1), which is among the key compounds of ginsenoside, found in ginseng, may be a potent scavenger of ROS. To examine the potential protective effect of Grb1 in Aβ25-35-induced cytotoxicity, cells were pre-treated with Grb1 for 24 h, and then Aβ25-35 was added to the medium for an additional 24 h. Exposure to Aβ led to the accumulation of ROS and lipid peroxidation, eventually causing a decrease in the Bcl-2/Bax ratio, caspase-3 activation, cell apoptosis and cell death. Pre-treatment with Grb1 not only inhibited Aβ-induced ROS overproduction and lipid peroxidation, but also increased the Bcl-2/Bax ratio and attenuated caspase-3 activation, thereby improving cell survival. Grb1 may therefore act as a ROS scavenger, and such antioxidant properties may play a protective role against Aβ-induced cell injury. Further exploration of Grb1 antioxidant properties may provide novel therapeutic strategies for the treatment of Alzheimer's disease.

**Introduction**

Alzheimer's disease (AD) is the most common age-dependent neurodegenerative disorder (1,2). Its major neuropathological features include senile plaques, neurofibrillary tangles and neuronal loss. β-amyloid (Aβ) peptide, a 39-43 amino acid β-sheet peptide, is the major protein component of senile plaques in the AD brain. The deposition and excessive accumulation of Aβ has been proposed as a pivotal event in the pathogenesis of AD (3,4), although the precise mechanism by which Aβ induces neuronal death remains unclear. It is well established that Aβ possesses neurotoxic activity, which has been associated with peptide self-aggregation and leads to the formation of amyloid-like fibrils, and eventually to neuronal death through apoptosis. Several studies suggest that oxidative stress is involved in an apoptotic mechanism by which excessive ROS production leads to neuronal apoptosis in neurodegenerative disorders, such as Aβ-induced neuronal apoptosis (5-7). Aβ25-35 is a short Aβ fragment that exhibits large β-sheet fibrils and retains the same neurotoxicity as the full-length peptide (8). In this study, Aβ25-35 was selected as a model for full-length Aβ to induce neuronal damage.

Ginsenoside Rb1 (Grb1), which is among the key active compounds of ginsenoside, found in ginseng, has exhibited beneficial effects on memory and learning by facilitating cholinergic function and increasing synaptophysin levels in the hippocampus (9). Recently, it was reported that Grb1 plays a role in neuronal protection in response to ischemia (10-12). Grb1 was reported to increase the expression of anti-apoptotic genes after transient cerebral ischemia *in vivo*. Previous studies have also suggested that Grb1 may act as a scavenger of toxic species, such as glutamate and hydrogen peroxide (13,14). Since oxidative stress is involved in neuronal apoptosis in AD, this raises the possibility that Grb1 may play a role in cellular defense against oxidative stress and neuronal apoptosis induced by Aβ. Taken together, these studies suggest that Rb1 may rescue or protect neurons from insult and is a pharmaceutical candidate for the treatment of AD. However, the protective effects of Grb1 on Aβ-induced neuronal apoptosis have yet to be reported.

We therefore chose to investigate the effects of Grb1 on Aβ25-35-induced neuronal apoptosis and its underlying mechanism. The rat pheochromoctomy cell line (PC12), a common model for neuronal functional studies, was used. Changes in the production of ROS and MDA, Bcl-2 family proteins and caspase-3 activity were examined, and the effects of Grb1
on Aβ25-35-induced injury were reported. To the best of our knowledge, this is the first study to demonstrate that ginsenoside Rb1 protects neuron from oxidative stress-induced cell injury in AD.

Materials and methods

Materials. Aβ25-35, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide (PI) were purchased from Sigma. RPMI-1640, fetal bovine serum and horse serum were purchased from Hyclone. Antibodies were purchased from Santa Cruz. The ROS detection kit was purchased from Beijing Applygen Technologies. GRβ1 was purchased from China's National Institute for the Control of Pharmaceutical and Biological Products. SABC, DAB and MDA kits were purchased from Boster Biological Technology Ltd. (Wuhan, P.R. China). Aβ25-35 was prepared in a 1 mM stock solution in phosphate-buffered saline (PBS) at -20°C, and aggregated overnight at 37°C before use. The stock solution was then diluted to the desired concentrations.

Cell culture and treatment. PC12 cells were grown in RPMI-1640 containing 10% heat-inactivated horse serum and 5% fetal bovine serum at 37°C in a 5% CO2 atmosphere. The medium was changed every other day and cells were plated at the appropriate density according to each experimental scale. To study the effects of GRβ1 on Aβ25-35-induced cell injury, cells were pre-incubated with GRβ1 for 24 h, and then Aβ25-35 was added to the medium for an additional 24 h. The experimental groups were: A, control; B, 25 µM Aβ25-35; C, 0.01 mM GRβ1 + 25 µM Aβ25-35; D, 0.1 mM GRβ1 + 25 µM Aβ25-35; E, 1 mM GRβ1 + 25 µM Aβ25-35. Following pre-treatment with GRβ1 and treatment with Aβ, the cells were subjected to the MTT assay and flow cytometry analysis, the measurement of ROS and MDA, Western blotting and immunocytochemistry.

MTT assay. Cell viability was measured by a quantitative colorimetric assay with MTT, which shows the mitochondrial activity of living cells. PC12 cells in 96-well plates were incubated with Aβ25-35 for 24 h. Subsequently, 0.5 mg/ml MTT was added to each well and cells were incubated for 4 h at 37°C. After the medium containing MTT was removed, cells and dye crystals were lysed in 100 µl DMSO by gentle agitation of the plate for 10 min, and the absorbance was read at 490 nm.

Flow cytometric analysis. To quantify the number of apoptotic cells, cells were harvested and washed twice with cold PBS. After fixation in 70% ethanol at 4°C overnight, the cells were centrifuged at 200 x g for 10 min and resuspended in 100 µl PBS containing 50 µg/ml RNase A at 37°C for 30 min. The cells were then incubated in 500 µl PBS containing 50 µg/ml PI at 4°C for 1 h in the dark. The fluorescence of cells was measured with a FACScan flow cytometer.

Measurement of ROS. Determination of intracellular oxidant production in PC12 cells was based on the oxidation of DCFH-DA by intracellular ROS, resulting in the formation of the fluorescent compound 2',7'-dichlorofluorescin (DCF). Cells were incubated with 1 µg/ml 2',7'-DCFH-DA for 45 min at 37°C. After the cells were washed twice with PBS, DCF fluorescence was monitored with a Hitachi F-2000 Spectrofluorimeter (excitation, 485 nm; emission, 538 nm).

Measurement of MDA. MDA, an index of lipid peroxidation, was measured by a commercial assay using the thiobarbituric acid method. The measurement was based on the conjugation ability of MDA with thiobarbituric acid (TBA) to form a red product with a maximum absorbance of 532 nm.

Western blot analysis. Cells were homogenized by standard procedures. Protein concentrations were determined using the Bradford protein assay. Proteins (50 µg) were heated for 10 min at 95°C and loaded on to 12% SDS-PAGE, then transferred electrophoretically onto nitrocellulose membranes and blocked in 5% non-fat milk for 2 h at 4°C. The blots were then incubated with I antibody (anti-Bcl-2, 1:200; anti-Bax, 1:200; anti-β-actin, 1:1,000) overnight at 4°C and II antibody (HRP IgG, 1:5,000) for 1 h at room temperature, then subjected to autoradiography (ECL reagents; Amersham Pharmacia Biotech, Buckinghamshire, UK). The optical density (OD) was analyzed by the Gel Image Analysis System (Tanon 2500R, Shanghai, P.R. China).

Immunocytochemistry. Evaluation of active caspase-3 expression was performed according to the protocol of the SABC immunocytochemistry kit. Briefly, the cell slices were fixed in 4% paraformaldehyde for 30 min, then incubated with caspase-3 antibody (1:200) at 4°C overnight and with biotinylated secondary antibody for 10 min. After being reacted with a streptavidin-biotin-peroxidase complex for 30 min, immunoreactivity was determined by 3,3’-diaminobenzidine. To better appreciate negative nuclei, the slices were counterstained with hematoxylin. Negative control sections were stained in an identical fashion, with caspase-3 antibody omitted. The evaluation of positive cells was conducted by examining yellow or brown granules in the cytoplasm or nucleus.

Statistical analysis. Results are expressed as the means ± standard error of the mean (SEM), and were analyzed using SPSS 13.0 software. Statistical significance was determined by one-way analysis of variance (ANOVA) followed by the Tukey test when appropriate. P<0.05 was considered statistically significant.

Results

Effect of GRβ1 on cell viability and apoptosis. After incubation with 25 µM Aβ25-35 for 24 h, the cell viability of the PC12 cells was determined using the MTT assay. As shown in Fig. 1, 25 µM Aβ25-35 significantly decreased the cell viability compared to the control group (P<0.01). However, pre-treatment with different concentrations of GRβ1 significantly increased the cell viability of Aβ25-35-treated PC12 cells in a dose-dependent manner (P<0.05). Further examination revealed that Aβ25-35 induced a significant increase in the apoptosis rate, which was defined as the percentage of cells with subdiploid DNA content determined by flow cytometry. Similar to the preventive effects of GRβ1 on the cell death, GRβ1 dose-dependently and significantly decreased apoptosis (P<0.05) (Fig. 2).
Effect of GRb1 on oxidative stress in Aβ25-35-treated PC12 cells. After 24 h of exposure to Aβ25-35, DCF fluorescence intensity in the PC12 cells was significantly increased compared to the control (P<0.01) (Fig. 3A). This increase in DCF fluorescence intensity was inhibited in a dose-dependent manner by pre-treatment with various concentrations of GRb1 (P<0.05).

Effect of GRb1 on lipid peroxidation in Aβ25-35-treated PC12 cells. After 24 h of exposure to Aβ25-35, an increase in the lipid peroxidation level of the PC12 cells of 200-250% compared to the control was observed. This was indicated by the excessive formation of MDA in the cells (Fig. 3B). GRb1 pre-treatment significantly decreased the formation of MDA as compared to levels observed in the Aβ25-35 group (P<0.05), but no significant difference was observed with different concentrations in the GRb1 group.

Effect of GRb1 on the ratio of Bcl-2/Bax in Aβ25-35-treated PC12 cells. It is well known that the ratio of Bcl-2/Bax is regulated in response to cellular stress, including oxidative stress. We therefore examined the expression of Bcl-2 and Bax protein by Western blotting. After 24 h of exposure of the PC12 cells to 25 µM Aβ25-35, Bcl-2 expression was down-regulated, while Bax expression was up-regulated. The ratio
of Bcl-2/Bax was decreased compared to the control (Fig. 4). In cells pre-treated with various concentrations of GRb1, Bcl-2 protein increased and Bax protein decreased compared to cells treated with Aβ25-35 alone. The ratio of Bcl-2/Bax protein increased compared to the Aβ25-35 group.

**Effect of GRb1 on caspase-3 activity in Aβ25-35-treated PC12 cells.** Active caspase-3 is the final executor of apoptotic DNA damage, and its activity is a characteristic of apoptosis. Immunocytochemistry was used to determine the expression level of active caspase-3. Mixed nuclear-cytoplasmic immuno-positive neurons were evident in the Aβ25-35 group. The protein expression level of active caspase-3 was increased in the Aβ25-35 group alone. By contrast, the protein expression level of active caspase-3 was decreased in PC12 cells treated with various concentrations of GRb1 (Fig. 5).

**Discussion**

In this study, Aβ treatment of PC12 cells induced oxidative stress and cell injury, accompanied by a significant increase in ROS production and lipid peroxidation, culminating in apoptotic cell death. These effects were prevented by GRb1 pre-treatment. Our data showed that GRb1 not only decreased Aβ-induced overproduction of ROS and lipid peroxidation, but also attenuated Aβ-induced cell apoptosis and cell death.

Ginseng root has been widely prescribed in China for thousands of years for a variety of ailments, particularly those associated with aging and memory deterioration. To date, more than 40 ginsenosides have been isolated from ginseng root and chemically identified. GRb1 (one protopanaxadiol type saponin) is one of the key active compounds of ginseng. GRb1 was recently found to play a role in neuronal cell protection against ischemic insult (15,16). The mechanisms of GRb1 neuroprotection under ischemic stress may be related to the up-regulation of the anti-apoptotic protein expression of Bcl-2 and Bcl-XL, and the down-regulation of the pro-apoptotic protein expression Bax, which inhibited apoptosis by preventing the release of cytochrome c. It is conceivable that GRb1 operates as a ROS scavenger, considering its properties in vitro against toxic reactive species, such as hydrogen peroxide and glutamate (13,14). Since oxidative stress is involved in the neurodegenerative process of AD, GRb1 may prevent the oxidative stress-induced neuronal apoptosis caused by Aβ.

Oxidative stress reflects a situation in which ROS is continuously produced and exceeds the capacity of endogenous antioxidant defense systems. Several studies have suggested that oxidative stress plays a key role in Aβ-mediated neuronal cytotoxicity by triggering or facilitating neurodegeneration through a wide range of molecular events that eventually lead to neuronal cell loss (17-19). Aβ significantly increases ROS production and enhances membrane lipid peroxidation, leading to neuronal apoptosis. It has been demonstrated that antioxidants have a beneficial effect in Aβ-induced neurotoxicity (20) and neurodegenerative disorders (21,22). Therefore, in AD, antioxidant therapies may delay the occurrence of apoptosis or prevent it altogether. In the present study, we showed that the presence of Aβ not only increased ROS overproduction, but was also associated with lipid...
peroxidation in PC12 cells. These findings are consistent with the results of previous studies. Furthermore, GRβ1 decreased ROS overproduction as well as lipid peroxidation in PC12 cells. Thus, the antioxidant properties of GRβ1 may indeed provide a novel and effective neuroprotective approach against the oxidative injury induced by Aβ, particularly when considering that antioxidants attenuate Aβ-induced oxidative injury.

In the present study, we found that Aβ treatment not only induced the production of excess ROS, but also caused apoptosis and cell death in PC12 cells. Considering the strong correlation between Aβ-induced oxidative stress and cytotoxicity (17-19), ROS produced in mitochondria may leak to the cytoplasm, leading to oxidative stress and the initiation of apoptosis via the activation of apoptosis signaling (23). It is well established that the ratio of Bcl-2/Bax is crucial in the apoptosis of the mitochondrial pathway. Bcl-2 is a potent cell death suppressor, and its overexpression prevents cell death. However, Bax is a death-promoting factor, and its translocation to the mitochondrial membrane may lead to the loss of mitochondrial membrane potential and an increase in mitochondrial permeability. Increased mitochondrial permeability results in the egress of cytochrome c from the mitochondria and the subsequent activation of procaspase-3 to caspase-3, which eventually leads to apoptosis (24,25). We found that Aβ treatment significantly decreased the Bcl-2/Bax protein expression ratio and increased caspase-3 activity, in agreement with previous reports. Concurrently, we measured the effects of GRβ1 on this process to clarify its neuroprotective mechanism. Our results indicate that GRβ1 significantly increased the Bcl-2/Bax ratio and decreased caspase-3 activity induced by Aβ, suggesting that GRβ1 is capable of decreasing Aβ-induced apoptosis. Based on these findings, we postulate that the anti-apoptotic effect of GRβ1 may be mediated by its antioxidant properties.

In conclusion, our data show that exposure to Aβ leads to the accumulation of ROS and lipid peroxidation, eventually leading to a decrease in the Bcl-2/Bax ratio, subsequent caspase-3 activation, cell apoptosis and cell death. However, GRβ1 was found to not only inhibit Aβ-induced ROS overproduction and lipid peroxidation, but also to increase the Bcl-2/Bax ratio and attenuate caspase-3 activation, thereby improving cell survival. GRβ1 may therefore act as a ROS scavenger, and such antioxidant properties may play a protective role against Aβ-induced cell injury. Further exploration of GRβ1 antioxidant properties may provide novel therapeutic approaches aimed at preventing or palliating the consequences of AD.

References